Literature DB >> 12444552

The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation.

Tara L F Buckwalter1, Anjli Venkateswaran, Marc Lavender, Krista M D La Perle, Je-Yoel Cho, Michael L Robinson, Sissy M Jhiang.   

Abstract

RET/PTC1 is a rearranged form of the RET proto-oncogene detected in human papillary thyroid carcinomas. We previously showed that thyroid-targeted expression of RET/PTC1 leads to thyroid tumor formation in Tg-PTC1 transgenic mice. Signal transduction pathways mediated by phosphotyrosine 294, 404, or 451 in RET/PTC1 have been shown to be critical for RET-induced transforming activity in vitro. To investigate the contribution of these signaling pathways in RET/PTC1-induced thyroid tumor formation in vivo, we generated and characterized transgenic mice expressing thyroid-targeted RET/PTC1 mutants carrying a site-directed mutation changing tyrosine (Y) to phenylalanine (F) at the residue 294, 404, or 451. In contrast to the 100% tumor formation rate in Tg-PTC1 transgenic mice, tumor formation rates were significantly decreased in Tg-PTC1-Y294F (6%), Tg-PTC1-Y404F (41%), and Tg-PTC1-Y451F (30%) transgenic mice. This indicates that signaling pathways mediated by pY294, pY404, and pY451 do play a role in RET/PTC1-induced tumor formation. However, as tumors are still able to form in some mice within these three mutant transgenic groups, it indicates that none of the signaling pathways mediated by pY294, pY404, or pY451, are solely essential for RET/PTC1-induced tumor formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444552     DOI: 10.1038/sj.onc.1205938

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

2.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 3.  Mouse models of endocrine tumours.

Authors:  Georgette N Jones; Parmeet K Manchanda; Daphne R Pringle; Mei Zhang; Lawrence S Kirschner
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 4.  Mouse models of thyroid cancer: A 2015 update.

Authors:  Lawrence S Kirschner; Zahida Qamri; Suresh Kari; Amruta Ashtekar
Journal:  Mol Cell Endocrinol       Date:  2015-06-27       Impact factor: 4.102

5.  Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death.

Authors:  Antonio Pedro Goncalves; Arnaldo Videira; Valdemar Maximo; Paula Soares
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

6.  The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression.

Authors:  K Balogh; S L Asa; L Zheng; C Cassol; S Cheng; S Ezzat
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.